Overview
Ipamorelin is a synthetic pentapeptide classified as a selective growth hormone secretagogue (GHS) that has gained attention in research and off-label wellness communities for its potential effects on body composition, recovery, and metabolic health. Unlike exogenous growth hormone injections, ipamorelin works by stimulating the body's own pituitary gland to release endogenous GH—a mechanism that theoretically preserves natural hormone pulsatility and carries a lower side-effect burden than direct GH administration.
This compound mimics the action of ghrelin, a natural hormone that signals hunger and stimulates GH release. What distinguishes ipamorelin in the crowded peptide marketplace is its selectivity: at therapeutic doses, it shows minimal impact on cortisol, prolactin, or ACTH—hormones that can become problematic with other GH secretagogues. However, it is important to emphasize that ipamorelin is not FDA-approved for human use, is banned by WADA in athletic competition, and remains a research compound with limited long-term safety data in humans.
This article provides a comprehensive, evidence-based overview of ipamorelin's proposed benefits, dosing protocols, side effects, and what the actual research says about its efficacy.
How It Works: Mechanism of Action
Ipamorelin exerts its effects through a well-characterized molecular pathway. It binds selectively to the ghrelin receptor (GHS-R1a) located in the pituitary gland and hypothalamus. This binding triggers activation of Gq/G11 and Gi protein signaling cascades, which in turn stimulate dose-dependent release of endogenous growth hormone from somatotroph cells.
Once released into circulation, GH acts systemically to promote downstream production of insulin-like growth factor-1 (IGF-1) in the liver. IGF-1 is considered the primary mediator of many of ipamorelin's proposed anabolic, lipolytic (fat-burning), and tissue-regenerative effects.
A key mechanistic advantage of ipamorelin relative to older GH secretagogues is its lack of somatostatin suppression. Somatostatin is a natural inhibitor of GH release; compounds that blunt its activity can lead to compensatory GH desensitization over time. Ipamorelin preserves normal somatostatin function, which means the pulsatile nature of GH secretion remains intact at standard research doses—potentially allowing for more physiologic GH dynamics and reduced tolerance development.
In human pharmacokinetic studies, ipamorelin demonstrates a rapid onset and short half-life of approximately 2 hours, with peak GH concentrations occurring roughly 40 minutes after injection.
Evidence by Health Goal
The evidence supporting ipamorelin varies substantially across proposed uses. Below is a breakdown of what the research actually shows for each commonly cited benefit.
Fat Loss: Tier 2 Evidence
Summary: Limited and mixed evidence. Animal studies suggest ipamorelin may not reliably promote fat loss and may even increase body fat in some contexts.
In a ferret model of cisplatin-induced cachexia (chemotherapy-related wasting), ipamorelin administered at 1–3 mg/kg inhibited weight loss by approximately 24% during the 48–72 hour post-treatment window compared to placebo. This represents a potential preservation of body mass in a disease state, though the context is highly specific.
However, in mice, ipamorelin treatment actually increased fat pad weights relative to body weight in both GH-deficient and GH-intact animals—a result that contradicts the fat-loss narrative and suggests that GH stimulation alone may not reliably drive lipolysis in all contexts, or that ipamorelin may have GH-independent effects promoting adiposity.
Bottom line: No human efficacy data for fat loss exists. Animal evidence is contradictory. Claims of fat-loss benefit are not supported by current research.
Muscle Growth: Tier 2 Evidence
Summary: Ipamorelin stimulates GH secretion and increases bone mineral content in animal models, but no rigorous human efficacy trials for muscle growth have been conducted.
In female rats, ipamorelin at 0.5 mg/kg/day for 12 weeks increased total tibial and vertebral bone mineral content. When corrected for body weight gain, the effect was less pronounced, suggesting the benefits may be partly attributable to overall growth rather than selective muscle anabolism.
In steroid-treated rats, the combination of ipamorelin and glucocorticoids increased periosteal bone formation rate four-fold compared to glucocorticoid alone over 3 months—demonstrating a potential synergistic effect in a disease-relevant model.
Bottom line: Bone mineral content increases are documented in animal models; direct evidence for lean muscle growth in humans is absent.
Injury Recovery: Tier 2 Evidence
Summary: Purely theoretical in humans. No clinical trials exist.
Ipamorelin is mentioned in mechanistic reviews as a candidate for injury recovery due to its GH-secretagogue properties and theoretical ability to activate IGF-1 signaling and satellite cell repair pathways. However, zero human clinical trials have tested whether ipamorelin actually accelerates recovery from acute injury or surgery (except for the gut health trial described below).
Bottom line: Mechanism is plausible but unproven in humans. Do not expect established clinical benefit.
Anti-Inflammatory Effects: Tier 2 Evidence
Summary: Promising mechanistic evidence in rodent pain models; no human evidence.
In rat studies, ipamorelin significantly attenuated colonic hypersensitivity and somatic mechanical allodynia (pain). These anti-nociceptive (pain-reducing) effects were blocked by the ghrelin receptor antagonist H0900, confirming that the effects depend on ghrelin receptor activation.
In glucocorticoid-treated rats, ipamorelin combined with methylprednisolone showed improved outcomes on bone formation, a proxy for tissue health in an inflammatory context.
Bottom line: Rodent models suggest anti-inflammatory and anti-pain potential; human evidence is absent.
Mood & Stress: Tier 1 Evidence
Summary: No evidence.
The available literature on ipamorelin includes four studies, all of which focus exclusively on GH secretion, bone growth, and chemotherapy-induced weight loss in animals. None assess mood, anxiety, depression, or stress-related outcomes in any population.
Bottom line: Do not use ipamorelin for mood or stress support. No basis in evidence.
Sleep: Tier 1 Evidence
Summary: No evidence.
Ipamorelin is mentioned as a growth hormone secretagogue in a single review article, but no sleep-specific efficacy data is provided. Other peptides (epithalon, delta sleep-inducing peptide, pinealon) are attributed with sleep-regulatory properties in that review—not ipamorelin.
Bottom line: No evidence for sleep improvement.
Energy: Tier 1 Evidence
Summary: No evidence.
The only available source is an abstract from a doping control analytical method paper that mentions ipamorelin as "orally active" and capable of inducing GH production, but reports zero efficacy data for energy, fatigue, or performance.
Bottom line: No basis for energy claims.
Gut Health: Tier 3 Evidence
Summary: Modest evidence from one human trial for postoperative recovery.
In a double-blind, multicenter RCT (n=114), ipamorelin at 0.03 mg/kg administered intravenously twice daily for 1–7 days post-operatively reduced median time to first tolerated meal from 32.6 hours (placebo) to 25.3 hours—a reduction of approximately 7.3 hours. This represents the strongest human evidence for ipamorelin efficacy to date.
Adverse events occurred in 87.5% of the ipamorelin group versus 94.8% in the placebo group, indicating a favorable safety profile in this human population.
Bottom line: Modest benefit for postoperative ileus; evidence is limited to a single trial and lacks independent replication.
Heart Health: Tier 1 Evidence
Summary: No clinical evidence.
Available abstracts address doping detection and mechanistic observations (e.g., ghrelin receptor overexpression in heart failure) but report no actual heart health outcomes or clinical trials in humans.
Bottom line: No evidence supports ipamorelin for cardiovascular health.
Liver Health: Tier 2 Evidence
Summary: Animal mechanistic data; no human evidence.
In prednisolone-treated rats, ipamorelin reduced hepatic urea-nitrogen synthesis capacity by 20% compared to prednisolone alone (p<0.05). It also normalized nitrogen balance in steroid-treated rats and improved organ nitrogen content—metabolic changes relevant to liver function but not proven to translate to clinical benefit in humans.
Bottom line: Animal data suggest metabolic effects; human efficacy is unproven.
Hormonal Balance: Tier 2 Evidence
Summary: Ipamorelin reliably stimulates GH release in humans; clinical efficacy for hormonal health goals is unproven.
In a human RCT with 40 healthy volunteers, ipamorelin induced dose-proportional GH release with an SC50 (dose producing 50% maximal response) of 214 nmol/L and a maximal GH production rate of 694 mIU/L/hour. Peak GH concentration occurred approximately 40 minutes post-injection with a short 2-hour half-life.
In rats, ipamorelin increased tibial area bone mineral density and cortical bone mineral content, though total body mineral content corrected for weight gain was unchanged.
Bottom line: GH stimulation is established in humans; whether this translates to clinical benefit for hormonal health is unknown.
Sexual Health: Tier 1 Evidence
Summary: Only a fish study exists; no human evidence.
In tilapia, ipamorelin produced dose-dependent increases in spermatocyte development and testosterone levels at 5–30 µg doses over 21 days. The 30 µg dose significantly increased late spermatid numbers and testicular lobule/lumen areas.
Bottom line: No human evidence whatsoever. Fish data does not translate to humans.
Athletic Performance: Tier 1 Evidence
Summary: Mentioned in passing in one narrative review; no actual efficacy data reported.
Ipamorelin appears in a single narrative review as part of a 'CJC-1295 + ipamorelin' combination discussion, but no specific efficacy data, human trials, or athletic performance outcomes are reported.
Bottom line: No evidence for athletic performance enhancement.